Israeli Start-Up Alcobra Develops New Treatment for Attention Deficit Disorder

December 2, 2013 3:26 pm 2 comments
Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israeli pharmaceutical start-up Alcobra Pharmaceuticals is listed on the NASDAQ electronic stock exchange under the ticker ADHD, the disease it treats with a non-stimulant compound that is expected to come to the market in 2015.

In an interview with Israeli business daily Globes, CEO Dr. Yaron Daniely explained how the company was originally created in 2008 to develop the molecule metadoxine to help inhibit the effects of alcohol on the brain.

“The goal was to create a pill that would quickly reduce blood alcohol levels, so that people would be able to drive safely,” explains Daniely. “It turned out the drug had no significant impact on removing alcohol from the blood, but it had a very significant impact on cognitive ability. In driving, memory, and attention tests that were conducted, it was as though those people were not drunk, despite the fact that, in terms of the amount of alcohol in their blood, it was not clear that they would be able to stand on their own two feet. So the idea to treat Attention Deficit Disorder came about.”

A pilot the company conducted in 2010 among 40 adults with ADHD showed “an immediate and significant improvement in attention tests. As a result of this, the company reinvented itself,” Daniely said, which is when he was named by researchers Dr. Dalia Megiddo and Udi Gilboa to be its new CEO.

Bilingual with a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine, an NIH Visiting Fellow in Cell Biology, a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science, in Rehovot, and an MBA from the Technion – Israel Institute of Technology, Daniely also was VP Business Development at Gamida Cell Ltd., managing its joint venture with Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) to develop a cancer drug.

The idea was to approach TEVA to fund the start-up, which it did with $5 million to fund its first tests. But with TEVA later in a management crisis, and its options to increase its position in Alcobra expired, the team sought an IPO on the NASDAQ, which has since net it some $60 million in proceeds and a market capitalization of $220 million, more than enough to fund its final tests and market launch.

Daniely said the chemical compound metadoxine has been approved for 40 years for the treatment of liver disease in third-world countries, including India, China, Russia, and Thailand. The company has registered a patent for the use of metadoxine for neurological conditions, through a timed-release of the substance, so its effect on the patient lasts a few hours.

Globes said that Alcobra has no labs, its raw materials are manufactured by a third party in Germany, and the pills themselves are manufactured in the US. The company believes that the drug combines the benefits of the two existing classes of ADHD drugs – the stimulants, such as Ritalin and Concerta, and the non-stimulant drugs, such as Strattera – and claims that it does not have their drawbacks.

According to the company, the results of the clinical trials showed that the drug is not addictive, worked faster and was twice as effective as the existing non-stimulant drugs, and had a similar anti-ADHD effect to that of the stimulants. It primarily affects cognitive ability, less so hyperactivity.

Daniely advised other Israeli start-ups to follow four lessons from Alcobra’s successful IPO. “The first element was quality, and a refusal to compromise,” he said. “Alcobra, from day one, tried to be different from other companies. We have an almost pedantic stubbornness not to do things too small or too short, but rather to do the things the way we would if we were a company in Silicon Valley. Therefore, our Phase II trial didn’t include 20 people over two weeks, instead, it included 120 people, with a placebo control, over the course of six weeks, using the exact same measures that all the ADHD drugs in the world are measured by. Many companies understand too late that they are conducting poorer trials without the appropriate controls.”

The second element was the company’s target market. “There’s nothing like ADHD,” he says. “First of all, people understand the market; there are drugs, it is known how much each company is selling and why, there are patients, there is a market that turns over $4 billion each year in the US. Also, people think they understand what ADHD is. It affects almost everyone, their kid, or their nephew.”

A third element is the pace of development: “With ADHD, unlike rare cancers, participants for clinical trials are incredibly easy to find. So our time to market and our ability to build our development process are such that almost every month we have good news for shareholders. The phase III trial will include 300 patients, in 20 medical centers, over the course of six months.”

The fourth element that helped secure funding was his native-English speaking ability, personal CV and track record and a decision to invite well-known professionals from the ADHD research community to be on their team, in this case, Prof. Lenard Adler, a researcher from NYU and an expert in ADHD drug development, who serves as head of the clinical committee that advises the company. “When someone like him sits next to you and says: ‘I conducted the trial and I stand behind the results,’ they can’t blow you off. Israeli entrepreneurs need to understand this and bring these people to their companies, so they can bridge the gap,” Daniely said.

While the company tried to get funding in Israel, where ADHD is less frequently diagnosed, its success in raising money on the NASDAQ has led many other young pharma companies to its doors, seeking advice. Its success has also led to new projects.

“Many things happened at the company, and our ability to implement plans grew. We had a tremendous opportunity to treat fragile X syndrome, which is associated with autism. It is a very common condition, which is very difficult for many who suffer from it, and there is no treatment. In a trial we conducted on animals with a kind of fragile X, we came up with outstanding results. It completely normalized learning, memory, social behavior, and communication. In parallel, the market in the US was still on fire, and said, ‘go, secure the investment, and bring in more cash,’” Daniely said.

The funds Alcobra raised guarantee that the company will have full funding until it is approved as a drug for adult ADHD, which, according to Daniely, is expected to reach market in late 2015, and for children soon afterwards. The money will also fund the fragile X trial.

2 Comments

  • In this period of financial crisis, you usually do not have to spend huge amount of money just to find out girls
    get their clothes off in front individuals. You have to discover once the nude models from the sex chat website can be extremely beautiful and
    deliciously attractive. Military husbands stationed in the Middle
    East have been in a position to witness the birth of an youngster through webcams.

  • Davida Rosenberg

    Please update me when this will be available in the U.S.
    A family member age 36 male.. has suffered his whole young life with this condition.

Leave a Reply

Please note: comments may be published in the Algemeiner print edition.


Current day month ye@r *

More...

  • Arts and Culture Theater US & Canada New Play Explores the ‘Arrogance’ of American Jews Critical of Israel, Playwright Says

    New Play Explores the ‘Arrogance’ of American Jews Critical of Israel, Playwright Says

    In his new play Mr. Goldberg Goes to Tel Aviv, playwright Oren Safdie tackles an issue that he has a major concern with: the relationship between Israelis and left-leaning Diaspora Jews with their “I know better” critical views. At the heart of the one-act play is Tony, a Jewish and gay Palestinian sympathizer who expresses strong anti-Israel sentiments when the play begins and at one point even sides with a Palestinian terrorist who holds his captive. Tony, who is also an [...]

    Read more →
  • Music US & Canada Hassidic Parody of Taylor Swift Song Apes Long Jewish Holidays (VIDEO)

    Hassidic Parody of Taylor Swift Song Apes Long Jewish Holidays (VIDEO)

    A Jewish comedy troupe released a parody video on Wednesday of Taylor Swift’s hit song Shake It Off in which they joke about taking extensive time off from work for Jewish holidays. “And the goyim gonna stay, stay, stay, stay, stay. And the Jews are gonna pray, pray pray, pray, pray. I’m just gonna take, take, take, take, take. I’m taking off,” goes the chorus for I’m Taking Off. Menachem Weinstein, the video’s lead singer, is the creative director at [...]

    Read more →
  • Arts and Culture Jewish Literature On 75th Anniversary, Looking at the Jewish Influence on Gone With the Wind

    On 75th Anniversary, Looking at the Jewish Influence on Gone With the Wind

    JNS.org – The 75th anniversary of the premiere of “Gone with the Wind” on Dec. 15 presents an opportunity to examine the Jewish influence on one of the most popular films of all time. That influence starts with the American Civil War epic’s famed producer, David O. Selznick. Adjusted for inflation, “Gone with the Wind” remains the highest-grossing movie ever made. It earned the 1939 Academy Award for Best Picture, the same honor another Selznick film, “Rebecca,” garnered in 1940. Selznick [...]

    Read more →
  • Featured Music US & Canada EXCLUSIVE: Matisyahu Provides Most Extensive Analysis Yet of His Religious, Musical Evolution (INTERVIEW)

    EXCLUSIVE: Matisyahu Provides Most Extensive Analysis Yet of His Religious, Musical Evolution (INTERVIEW)

    Matisyahu got candid in an exclusive interview with The Algemeiner on Monday about his religious and musical journey – after shedding his Chassidic skin, yarmulke, long beard and all – from the start of his career in 2005 when he became a reggae superstar with hits King Without a Crown and Jerusalem. The singer-songwriter embarks on his Festival of Light tour this month, an annual Hanukkah event that stops in Montreal, New York, and other cities before ending in San Juan, [...]

    Read more →
  • Arts and Culture Personalities ‘Sheriff of Mars’ Unveils Endearing Life of Jewish Music Star Hidden in the Fields of France

    ‘Sheriff of Mars’ Unveils Endearing Life of Jewish Music Star Hidden in the Fields of France

    JNS.org – It was an era of steel strings, guitar heroes, and storytellers—high on heroin, rebellious. Outlaw country music, the hallmark of Nashville’s powerful and angry music scene of the 1970s, was the brew of greats such as Johnny Cash, Willie Nelson, and Townes Van Zandt. But there is another, little-known music hero of that era: Daniel Antopolsky. A Jewish lad from Augusta, Ga.—the son of immigrants who settled in the south and ran a hardware store on Main Street—the [...]

    Read more →
  • Arts and Culture US & Canada Iranian Actress Replaces Israel’s Gal Gadot for ‘Ben-Hur’ Remake

    Iranian Actress Replaces Israel’s Gal Gadot for ‘Ben-Hur’ Remake

    Iranian actress Nazanin Boniadi replaced Israeli star Gal Gadot as the female lead in the new Ben-Hur remake, Hollywood.com reported on Tuesday. The Homeland actress will play Esther, a slave that Ben-Hur sets free and falls in love with. Gadot quit the movie when it became clear that filming conflicted with her schedule for the Man of Steel sequel. The Israeli actress plays Wonder Woman in the superhero film Batman v. Superman: Dawn of Justice. Actor Jack Huston takes on the [...]

    Read more →
  • Book Reviews Personalities Biography Sheds New Light on David Ben-Gurion’s Place in Jewish History

    Biography Sheds New Light on David Ben-Gurion’s Place in Jewish History

    JNS.org – There is one sentence in “Ben-Gurion: Father of Modern Israel” that made me sit up in surprise. I thought that I knew the basic facts about how Israel came into being, but while describing what it was like in the days and hours before the state was declared, author Anita Shapira provides one important anecdote I was not aware of. On the 12th of May, the Zionist Executive met to decide what to do. Moshe Sharrett had just returned [...]

    Read more →
  • Arts and Culture US & Canada ‘Death of Klinghoffer’ Actress Compares Met Opera to ‘Schindler’s List’

    ‘Death of Klinghoffer’ Actress Compares Met Opera to ‘Schindler’s List’

    An actress starring in the controversial Met Opera The Death of Klinghoffer defended the show on Tuesday by comparing it to the 1993 Holocaust film Schindler’s List, New York Post reported. “To me, this was like [the movie] Schindler’s List. We make art so people won’t forget,’’ said the actress, who plays a captured passenger in the show and asked not to be identified. The Met Opera focuses on the infamous murder of Lower East Side Jewish resident Leon Klinghoffer, 69. The wheelchair-bound father of [...]

    Read more →



Sign up now to receive our regular news briefs.